Pharma industry witnesses 68 deals in October 2017
Deal value decreases to $7.1 billion when compared five months average of $10.6 billion
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
New diabetes therapeutics to steal ground from insulin therapies: GBI Research
Increased market diversification is expected due to patent expiries for major insulin products
FDA approves Roche drugs for rare types of blood, lung cancers
The drug is already approved for patients who have been treated with Pfizer's lung cancer drug Xalkori
Crohn’s Disease diagnosed incident cases set to increase in the 7MM to 2026
The burden of diagnosed Crohn’s Disease (CD) is expected to grow between 2016 and 2026 in the seven major markets
Flexion’s Zilretta poised to shakeup knee osteoarthritis marketplace
The company anticipates a steady stream of novel therapies to enter the OA marketplace over the next 10 years
Affluent market, medical tourism to steer best-in line drug delivery devices in India
Trends indicate that medical tourism will also bolster the demand for sophisticated devices
Novartis seeks European approval for cell therapy Kymriah
The immunotherapy Kymriah is a key element of Novartis’s efforts to bolster its portfolio of oncology drugs
GSK gets boost for early cancer hopes with breakthrough status
The decision by the Food and Drug Administration paves the way for a speedy regulatory review of the BCMA drug for multiple…
Biotech firms race to recruit good bugs in war on cancer
Certain bacteria seem to help in cancer by priming immune cells and smoothing the path for immunotherapy drugs known as PD-1 drugs
Merck’s drug gets US FDA approval
The drug is expected to be available from December, was approved both as a tablet and an injection